55 related articles for article (PubMed ID: 1581636)
21. On the structural basis of the hypertensive properties of angiotensin II: a solved mystery or a controversial issue?
Tzakos AG; Gerothanassis IP; Troganis AN
Curr Top Med Chem; 2004; 4(4):431-44. PubMed ID: 14965310
[TBL] [Abstract][Full Text] [Related]
22. [Structure-function organization of the angiotensin II molecule. II. Reverse structural problem].
Gogitidze TV; Popov EM
Bioorg Khim; 1993 Jul; 19(7):693-703. PubMed ID: 8373449
[TBL] [Abstract][Full Text] [Related]
23. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
Krovat EM; Langer T
J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist.
Wong PC; Hart SD; Chiu AT; Herblin WF; Carini DJ; Smith RD; Wexler RR; Timmermans PB
J Pharmacol Exp Ther; 1991 Nov; 259(2):861-70. PubMed ID: 1941632
[TBL] [Abstract][Full Text] [Related]
25. Nonpeptide angiotensin II receptor antagonists. III. Structure-function studies.
Chiu AT; Duncia JV; McCall DE; Wong PC; Price WA; Thoolen MJ; Carini DJ; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1989 Sep; 250(3):867-74. PubMed ID: 2778716
[TBL] [Abstract][Full Text] [Related]
26. Psychotropic effects of angiotensin II N-terminal fragments: Asp-Arg-Val-Tyr-Ile-His and Arg-Val-Tyr-Ile-His in rats.
Hoły Z; Braszko J; Wiśniewski K
Pol J Pharmacol; 1993; 45(1):31-41. PubMed ID: 8401757
[TBL] [Abstract][Full Text] [Related]
27. Determination of the structure of lipid vesicle-bound angiotensin II and angiotensin I.
Jalili PR; Dass C
Anal Biochem; 2008 Mar; 374(2):346-57. PubMed ID: 18162166
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and conformational features of human salivary mucin C-terminal derived peptide epitope carrying Thomsen-Friedenreich antigen: implications for its role in self-association.
Satyanarayana J; Gururaja TL; Narasimhamurthy S; Naganagowda GA; Levine MJ
Biopolymers; 2001 Apr; 58(5):500-10. PubMed ID: 11241221
[TBL] [Abstract][Full Text] [Related]
29. Elucidation of a specific binding site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes.
Hanesworth JM; Sardinia MF; Krebs LT; Hall KL; Harding JW
J Pharmacol Exp Ther; 1993 Aug; 266(2):1036-42. PubMed ID: 8355180
[TBL] [Abstract][Full Text] [Related]
30. Structural insight on the activity of type 1 angiotensin II peptide antagonists using MD simulations.
Preto MA; Melo A; Rodrigues LM; Maia HL; Ramos MJ
J Phys Chem B; 2008 Oct; 112(43):13620-8. PubMed ID: 18834172
[TBL] [Abstract][Full Text] [Related]
31. Psychotropic activity of angiotensin II and its fragments Val-Tyr-Ile-NH2 and Val-Tyr-Ile-His-NH2.
Własienko J; Braszko JJ; Koziołkiewicz W; Janecka A; Wiśniewski K
Biomed Biochim Acta; 1989; 48(9):707-13. PubMed ID: 2619739
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the solution structures of angiotensin I & II. Implication for structure-function relationship.
Spyroulias GA; Nikolakopoulou P; Tzakos A; Gerothanassis IP; Magafa V; Manessi-Zoupa E; Cordopatis P
Eur J Biochem; 2003 May; 270(10):2163-73. PubMed ID: 12752436
[TBL] [Abstract][Full Text] [Related]
33. Conformational study of angiotensin II.
Shin YA; Yoo SE
Biopolymers; 1996 Feb; 38(2):183-90. PubMed ID: 8589252
[TBL] [Abstract][Full Text] [Related]
34. Gross conformation of dissolved angiotensin derived from sedimentation and diffusion coefficients.
Behlke J; Ristau O
Biochem Soc Trans; 1998 Nov; 26(4):758-61. PubMed ID: 10047822
[No Abstract] [Full Text] [Related]
35. Theoretical conformational analysis of Asn1, Val5 angiotensin II.
De Coen JL; Ralston E
Biopolymers; 1977 Sep; 16(9):1929-43. PubMed ID: 901920
[No Abstract] [Full Text] [Related]
36. Conformation of angiotensin II in aqueous solution. Interpretation of the titration data according to the Kirkwood-Tanford theory [proceedings].
Juliano L; Paiva AC
An Acad Bras Cienc; 1978 Sep; 50(3):431. PubMed ID: 727596
[No Abstract] [Full Text] [Related]
37. Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors.
Vanderheyden PM; Verheijen I; Fierens FL; DeBacker JP; Vauquelin G
Pharm Res; 2000 Dec; 17(12):1482-8. PubMed ID: 11303957
[TBL] [Abstract][Full Text] [Related]
38. Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor.
Prendergast K; Adams K; Greenlee WJ; Nachbar RB; Patchett AA; Underwood DJ
J Comput Aided Mol Des; 1994 Oct; 8(5):491-512. PubMed ID: 7876897
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the active conformation of angiotensin II: a comparison of AII and non-peptide AII antagonists.
Pierson ME; Freer RJ
Pept Res; 1992; 5(2):102-5. PubMed ID: 1581636
[TBL] [Abstract][Full Text] [Related]
40. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations.
Mavromoustakos T; Kolocouris A; Zervou M; Roumelioti P; Matsoukas J; Weisemann R
J Med Chem; 1999 May; 42(10):1714-22. PubMed ID: 10346924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
